Literature DB >> 22635250

Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer.

Yong-Fang Kuo1, James E Montie, Vahakn B Shahinian.   

Abstract

BACKGROUND: Indication bias is the major challenge in assessing treatment effectiveness in observational studies. We explored the potential advantages of using an instrumental variable approach in the context of primary androgen deprivation therapy (ADT) for prostate cancer.
METHODS: We identified 31,930 men in the linked Surveillance, Epidemiology, and End Results-Medicare database with a diagnosis of prostate cancer who were not treated definitively with radical prostatectomy or radiation in the years 1992 through 2002, with follow-up through 2005. The association between use of primary ADT and overall, prostate cancer-specific, and nonprostate cancer survival was assessed using multivariable regression and instrumental variable methods. Two instrumental variables, based on region and urologist prescribing preference, were constructed and analyzed using exogenous probit models. Prespecified subgroup analyses in patients with lower-risk and higher-risk prostate tumors were also carried out.
RESULTS: In the overall cohort, standard multivariable regression analyses showed a significantly increased risk of prostate cancer-related death, whereas the instrumental variable approaches showed a protective effect of primary ADT, which was significant for the urologist preference instrument (hazard ratio: 0.74; 95% confidence interval, 0.60-0.93). In the high-risk subgroup, using urologist preference for primary ADT as the instrument, there was a significant reduction in overall mortality (hazard ratio: 0.75; 95% confidence interval, 0.57-0.99), driven by a large reduction in prostate cancer-specific mortality.
CONCLUSIONS: Instrumental variable analysis appears to provide better control of bias when assessing the effectiveness of primary ADT for prostate cancer, although the results may be more applicable to policy rather than to clinical decisions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22635250      PMCID: PMC3361681          DOI: 10.1097/MLR.0b013e318245a086

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  33 in total

1.  An introduction to instrumental variables for epidemiologists.

Authors:  S Greenland
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

2.  Bias and causal associations in observational research.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

3.  An exploratory instrumental variable analysis of the outcomes of localized breast cancer treatments in a medicare population.

Authors:  Jack Hadley; Daniel Polsky; Jeanne S Mandelblatt; Jean M Mitchell; Jane C Weeks; Qin Wang; Yi-Ting Hwang
Journal:  Health Econ       Date:  2003-03       Impact factor: 3.046

Review 4.  Critical evaluation of hormonal therapy for carcinoma of the prostate.

Authors:  Gerald W Chodak; Thomas Keane; Laurence Klotz
Journal:  Urology       Date:  2002-08       Impact factor: 2.649

5.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

Authors:  Michael J Pencina; Ralph B D'Agostino
Journal:  Stat Med       Date:  2004-07-15       Impact factor: 2.373

6.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 7.  Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

Authors:  Celestia S Higano
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

8.  Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.

Authors:  Jack Hadley; K Robin Yabroff; Michael J Barrett; David F Penson; Christopher S Saigal; Arnold L Potosky
Journal:  J Natl Cancer Inst       Date:  2010-10-13       Impact factor: 13.506

9.  Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.

Authors:  Urs E Studer; Dieter Hauri; Silvia Hanselmann; Dominique Chollet; Hans-Jürg Leisinger; Thomas Gasser; Edgar Senn; Felix B Trinkler; Reto M Tscholl; George N Thalmann; Daniel Dietrich
Journal:  J Clin Oncol       Date:  2004-10-15       Impact factor: 44.544

10.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Authors:  Anthony V D'Amico; Judith Manola; Marian Loffredo; Andrew A Renshaw; Alyssa DellaCroce; Philip W Kantoff
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

View more
  6 in total

1.  Prostate cancer: towards appropriate use of androgen deprivation therapy.

Authors:  Vahakn B Shahinian
Journal:  Nat Rev Urol       Date:  2013-02-19       Impact factor: 14.432

2.  Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

Authors:  Arnold L Potosky; Reina Haque; Andrea E Cassidy-Bushrow; Marianne Ulcickas Yood; Miao Jiang; Huei-Ting Tsai; George Luta; Nancy L Keating; Matthew R Smith; Stephen K Van Den Eeden
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.

Authors:  Jason D Wright; Cande V Ananth; Jennifer Tsui; Sherry A Glied; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman
Journal:  Cancer       Date:  2014-01-17       Impact factor: 6.860

Review 4.  A systematic review of instrumental variable analyses using geographic region as an instrument.

Authors:  Emily A Vertosick; Melissa Assel; Andrew J Vickers
Journal:  Cancer Epidemiol       Date:  2017-10-14       Impact factor: 2.984

5.  Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer.

Authors:  Jason D Wright; Yongmei Huang; William M Burke; Ana I Tergas; June Y Hou; Jim C Hu; Alfred I Neugut; Cande V Ananth; Dawn L Hershman
Journal:  Obstet Gynecol       Date:  2016-01       Impact factor: 7.661

6.  Evaluating comparative effectiveness with observational data: endoscopic ultrasound and survival in pancreatic cancer.

Authors:  Abhishek D Parmar; Kristin M Sheffield; Yimei Han; Gabriela M Vargas; Praveen Guturu; Yong-Fang Kuo; James S Goodwin; Taylor S Riall
Journal:  Cancer       Date:  2013-08-06       Impact factor: 6.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.